[Mechanism of action and preclinical development of afatinib]

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Afatinib, gefitinib, and erlotinib are approved for first-line treatment of advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations.
• Afatinib is an irreversible inhibitor of the ErbB family, including EGFR (HER1), ErbB2 (HER2), and ErbB4 (HER4).

Purpose of the Study:

• To elucidate the mechanism of action of afatinib as an irreversible ErbB family inhibitor.
• To compare the potential potency and resistance-overcoming capabilities of afatinib against first-generation EGFR TKIs.
• To explore the potential for afatinib in combination therapies for NSCLC.

Main Methods:

• Afatinib covalently binds to cysteine residues in the catalytic domain of EGFR, HER2, and ErbB4.
• Inhibition of tyrosine kinase activity (TKIs) blocks downstream signaling pathways regulating cell growth and apoptosis.
• Preclinical models were used to assess tumor size reduction.

Main Results:

• Afatinib's mechanism inhibits receptor auto- and transphosphorylation, blocking growth and apoptosis pathways.
• Preclinical studies demonstrated a reduction in tumor size.
• Afatinib may possess greater potency than gefitinib and erlotinib and could overcome acquired resistance.

Conclusions:

• Afatinib's irreversible inhibition mechanism offers a potent therapeutic strategy for EGFR-mutated NSCLC.
• Its potential to overcome resistance and synergize with other agents warrants further clinical investigation.
• Afatinib holds promise for enhanced clinical development, particularly in combination therapies.